| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 08/15/2002 | WO2002062833A2 Modified leptin with reduced immunogenicity |
| 08/15/2002 | WO2002062804A1 Oxazolyl-pyrazole derivatives as kinase inhibitors |
| 08/15/2002 | WO2002062803A1 Thienopyrimidine derivative |
| 08/15/2002 | WO2002062801A1 Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives, medicinal compositions, adenosine a3 receptor affinity agents, ocular tension lowering agents, preparations for preventing and treating glaucoma and method of lowering ocular tension |
| 08/15/2002 | WO2002062800A1 Bicyclic nitrogenous fused-ring compound |
| 08/15/2002 | WO2002062798A2 Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose |
| 08/15/2002 | WO2002062795A2 Dihydropyrazolopyridine compounds and pharmaceutical use thereof |
| 08/15/2002 | WO2002062794A2 Compounds |
| 08/15/2002 | WO2002062793A1 Thiazole compounds as tgf-beta inhibitors |
| 08/15/2002 | WO2002062792A1 Jnk inhibitor |
| 08/15/2002 | WO2002062789A1 Pyrazole compounds useful as protein kinase inhibitors |
| 08/15/2002 | WO2002062788A1 Sulfonamide compounds, their preparation and use |
| 08/15/2002 | WO2002062787A1 Pyrazoles as tgf inhibitors |
| 08/15/2002 | WO2002062786A1 Processes for the production of substituted 2-(2-pyridylmethyl) sulfinyl-1h-benzimidazoles |
| 08/15/2002 | WO2002062784A1 Piperidinee derivatives as neurokinin 1 antagonists |
| 08/15/2002 | WO2002062780A2 Phenoxy substituted benzocondensed heteroaryl derivatives as thyroid receptor ligands |
| 08/15/2002 | WO2002062777A2 Amino ceramide-like compounds and therapeutic methods of use |
| 08/15/2002 | WO2002062776A1 2-amino-4-(pyridin-2-yl)-thiazole derivatives as transforming growth factor beta (tgf-beta) inhibitors |
| 08/15/2002 | WO2002062774A1 Thiazole derivatives for treating ppar related disorders |
| 08/15/2002 | WO2002062773A1 Tricyclic lactam and sultam derivatives and their use as histone deacetylase inhibitors |
| 08/15/2002 | WO2002062767A1 Novel quinazoline derivatives |
| 08/15/2002 | WO2002062762A2 Potassium channel openers |
| 08/15/2002 | WO2002062751A1 Novel cystine derivatives and inhibitors for the activation of inflammatory factors |
| 08/15/2002 | WO2002062748A1 Carboxylic amides, the production and use thereof as medicaments |
| 08/15/2002 | WO2002062422A1 Novel compositions of potassium channel openers and protein kinase c inhibitors and use thereof |
| 08/15/2002 | WO2002062390A1 Medicinal compositions for treating lower uropathy |
| 08/15/2002 | WO2002062375A1 Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity |
| 08/15/2002 | WO2002062369A2 Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer |
| 08/15/2002 | WO2002062351A1 A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis |
| 08/15/2002 | WO2002062350A1 Methods for the administration of amifostine and related compounds |
| 08/15/2002 | WO2002062343A2 PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS |
| 08/15/2002 | WO2002062342A1 A method for the treatment of heart failure |
| 08/15/2002 | WO2002062335A2 Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts |
| 08/15/2002 | WO2002062323A2 Use of mglur5 antagonists for the treatment of pruritic conditions |
| 08/15/2002 | WO2002062306A1 Nos inhibitors for treatment of wrinkles |
| 08/15/2002 | WO2002062301A2 Method and composition for rejuvinating cells, tissues, organs, hair and nails |
| 08/15/2002 | WO2002062293A2 Coumarin compounds as microtubule stabilizing agents and therapeutic uses thereof |
| 08/15/2002 | WO2002042429A3 Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants |
| 08/15/2002 | WO2002042265A3 Cyanoguanidine prodrugs |
| 08/15/2002 | WO2002039948A3 Cross-linked hyaluronic acid-laminin gels and use thereof in cell culture and medical implants |
| 08/15/2002 | WO2002038035A3 Methods for inhibiting pain |
| 08/15/2002 | WO2002034753A3 Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 08/15/2002 | WO2002032861A3 Orally active salts with tyrosine kinase activity |
| 08/15/2002 | WO2002032419A3 Methods for modulating bladder function |
| 08/15/2002 | WO2002030860A3 Ketone compounds and compositions for cholesterol management and related uses |
| 08/15/2002 | WO2002028434A3 Use of a ppar delta activator for treating inflammatory conditions |
| 08/15/2002 | WO2002028433A3 Use of a ppar delta activator in the treatment of diseases related to no inhibit ion or tnf inhibition |
| 08/15/2002 | WO2002022212A8 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| 08/15/2002 | WO2002022160A3 The diagnosis, prevention, amelioration and/or treatment of disturbed immune function induced by disturbed lipid metabolism |
| 08/15/2002 | WO2002018369A3 Peptidomimetic protease inhibitors |
| 08/15/2002 | WO2002016381B1 Composition and method for inhibiting platelet aggregation |
| 08/15/2002 | WO2002011731A3 Use of the combination of nicotinic acid or derivatives with riboflavin in the manufacture of a medicament for the treatment of primary headaches |
| 08/15/2002 | WO2002011724A3 Neuroprotective 2-pyridinamine compositions and related methods |
| 08/15/2002 | WO2002002050A3 Prevention and treatment of mycoplasma-associated diseases |
| 08/15/2002 | WO2002000263A3 Tripeptide prodrug compounds |
| 08/15/2002 | WO2002000195A3 Methods and compositions for treating pain of the mucous membrane |
| 08/15/2002 | WO2002000175A3 Enhancing therapeutic effectiveness of nitric oxide inhalation |
| 08/15/2002 | WO2001095945A3 Prodrug compounds cleavable by thimet oligopeptidase |
| 08/15/2002 | WO2001072685B1 Polyamine analogues as cytotoxic agents |
| 08/15/2002 | WO2001061039A3 5-hydroxytryptamine transporter gene polymorphisms |
| 08/15/2002 | WO2001032877A9 CpG RECEPTOR (CpG-R) AND METHODS RELATING THERETO |
| 08/15/2002 | WO2001028545A9 Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis |
| 08/15/2002 | WO2001027135A9 Regulators of the hedgehog pathway, compositions and uses related thereto |
| 08/15/2002 | US20020111493 Amidino compounds useful as nitric oxide synthase inhibitors |
| 08/15/2002 | US20020111488 Beta-substitued beta-aminoethyl phosphonate derivatives |
| 08/15/2002 | US20020111486 Exhibits affinity for monoamine transporters useful in diagnosis of parkinson's disease |
| 08/15/2002 | US20020111378 Inhibitors of IMPDH enzyme |
| 08/15/2002 | US20020111375 Antitumor agents |
| 08/15/2002 | US20020111368 Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
| 08/15/2002 | US20020111364 ABCA-1 elevating compounds |
| 08/15/2002 | US20020111360 Quinazoline formulations and therapeutic use thereof |
| 08/15/2002 | US20020111359 Side effect reduction of narcotics |
| 08/15/2002 | US20020111358 Phenoxypropylamine compounds |
| 08/15/2002 | US20020111356 Phosphodiesterase inhibitor; antiinflammatory agents |
| 08/15/2002 | US20020111353 Antiinflammatory agents; central nervous system disorders;antidiabgetic agents; rheumatic disorders |
| 08/15/2002 | US20020111351 New hydroxyindoles, their use as inhibitors of phosphodiesterase 4 and processes for their preparation |
| 08/15/2002 | US20020111350 Aryl fused azapolycyclic compounds |
| 08/15/2002 | US20020111347 Nervous system disorders |
| 08/15/2002 | US20020111345 Use of taurolidine to treat tumors |
| 08/15/2002 | US20020111341 Bicyclic amino-pyrazinone compounds |
| 08/15/2002 | US20020111334 5-ASA derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith |
| 08/15/2002 | US20020111324 Adeno-associated virus-mediated delivery of angiogenic factors |
| 08/15/2002 | US20020111313 Tripeptide dosage |
| 08/15/2002 | US20020111306 DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof |
| 08/15/2002 | US20020111300 Methods for reduced renal uptake of protein conjugates |
| 08/15/2002 | US20020111299 Family of peptides known as xenoxins |
| 08/15/2002 | US20020110898 Attenuating endogenous genes in cell; obtain cell, transform with vectors conding restriction enzymes, recover and propagate transformed cells |
| 08/15/2002 | US20020110895 Nucleotide sequences coding enzymatic polypeptide for use in treatment of thrombosis and in the immune defects |
| 08/15/2002 | US20020110841 Regulation of cell growth by MUC1 |
| 08/15/2002 | US20020110840 Detecting modulators of interferon generation; obtain cells, incubate with modulator, monitor concentration of inflammatory cytokine, amplified cytokine concentration indicates modulators |
| 08/15/2002 | US20020110814 Method and kit for the screening, the detection and/or the quantification of transcriptional factors |
| 08/15/2002 | US20020110608 Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof |
| 08/15/2002 | US20020110560 Lowering elevated post-prandial blood glucose levels in mammals by increasing incretin half-life comprising administering inhibitor of Dipeptidyl Peptidase (DP IV) or enzymes having DP-IV-like activity |
| 08/15/2002 | US20020110545 Adenovector pharmaceutical composition |
| 08/15/2002 | US20020110529 Inhalable powder containing tiotropium |
| 08/15/2002 | CA2437717A1 G-protein coupled receptors |
| 08/15/2002 | CA2437571A1 Receptors and membrane-associated proteins |
| 08/15/2002 | CA2437453A1 Conformationally abnormal forms of tau proteins and specific antibodies thereto |
| 08/15/2002 | CA2437437A1 Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives, pharmaceutical, composition adenosine a3 receptor affinitive agent, intraocular-pressure reducing agent, pharmaceutical preparation for prevention and treatment of glaucoma, and intraocular-pressure reducing method |
| 08/15/2002 | CA2437434A1 Method for identifying compounds modulating reverse cholesterol transport |